human atrial trabeculae
Recently Published Documents


TOTAL DOCUMENTS

16
(FIVE YEARS 0)

H-INDEX

6
(FIVE YEARS 0)

2020 ◽  
Vol 319 (3) ◽  
pp. E540-E547
Author(s):  
Hamish M. Aitken-Buck ◽  
Aram A. Babakr ◽  
Ingrid C. Fomison-Nurse ◽  
Isabelle van Hout ◽  
Philip J. Davis ◽  
...  

The adipocytokine resistin is released from epicardial adipose tissue (EAT). Plasma resistin and EAT deposition are independently associated with atrial fibrillation. The EAT secretome enhances arrhythmia susceptibility and inotropy of human myocardium. Therefore, we aimed to determine the effect of resistin on the function of human myocardium and how resistin contributes to the proarrhythmic effect of EAT. EAT biopsies were obtained from 25 cardiac surgery patients. Resistin levels were measured by ELISA in 24-h EAT culture media ( n = 8). The secretome resistin concentrations increased over the culture period to a maximal level of 5.9 ± 1.2 ng/mL. Coculture with β-adrenergic agonists isoproterenol ( n = 4) and BRL37344 ( n = 13) had no effect on EAT resistin release. Addition of resistin (7, 12, 20 ng/mL) did not significantly increase the spontaneous contraction propensity of human atrial trabeculae ( n = 10) when given alone or in combination with isoproterenol. Resistin dose-dependently increased trabecula-developed force (maximal 2.9-fold increase, P < 0.0001), as well as the maximal rates of contraction (2.6-fold increase, P = 0.002) and relaxation (1.8-fold increase, P = 0.007). Additionally, the postrest potentiation capacity of human trabeculae was reduced at all resistin doses, suggesting that the inotropic effect induced by resistin might be due to altered sarcoplasmic reticulum Ca2+ handling. EAT resistin release is not modulated by common arrhythmia triggers. Furthermore, exogenous resistin does not promote arrhythmic behavior in human atrial trabeculae. Resistin does, however, induce an acute dose-dependent positive inotropic and lusitropic effect.


2017 ◽  
Vol 158 (1) ◽  
pp. 164-175 ◽  
Author(s):  
Ingra Mannhardt ◽  
Alexandra Eder ◽  
Berengere Dumotier ◽  
Maksymilian Prondzynski ◽  
Elisabeth Krämer ◽  
...  

2016 ◽  
Vol 71 (1) ◽  
pp. 25-30 ◽  
Author(s):  
L. N. Maslov ◽  
S. Yu. Tsibul'nikov ◽  
A. V. Mukhomedzyanov ◽  
A. S. Semenotsov ◽  
A. V. Tsepokina ◽  
...  

Experimental atherosclerosis and hypercholesterolemia may reduce or eliminate the infarct-limiting and anti-apoptotic effect of postconditioning (PC). Experiments in rats and mice indicate that the PC may be quite effective in patients with diabetes type 2 or metabolic syndrome. Experimental data suggest that hypertension or the past myocardial infarction is not an obstacle for the implementation of cardioprotective effect of PC. It was established that that aging does not preclude the implementation of PC cardioprotective effect. Inotropic effect of IP can simulate on isolated human atrial trabeculae. The clinical observations suggest that the PC in patients with tetralogy of Fallot and patients with operations on the valves improves the outcome of cardiac surgery. It was established that PC in these patients reduces the intensity of reperfusion necrosis of cardiomyocytes, improves the pumping function of the heart, reduces the inotropic support, shorten the extubation time.


Heart ◽  
2012 ◽  
Vol 98 (Suppl 1) ◽  
pp. A61.1-A61
Author(s):  
R Sirohi ◽  
L Candilio ◽  
G Babu ◽  
N Roberts ◽  
D Lawrence ◽  
...  

2010 ◽  
Vol 30 (5) ◽  
pp. 1476-1481
Author(s):  
Coşkun USTA ◽  
Paolo Emilio PUDDU ◽  
Francesco PAPALIA ◽  
Vincenzo De SANTIS ◽  
Luigi TRITAPEPE ◽  
...  

2007 ◽  
Vol 6 (11) ◽  
pp. 4458-4468 ◽  
Author(s):  
Florian M. Lampert ◽  
Peter Matt ◽  
Martin Grapow ◽  
Ivan Lefkovits ◽  
Hans-Reinhard Zerkowski ◽  
...  

2004 ◽  
Vol 44 (5) ◽  
pp. 622-625 ◽  
Author(s):  
Coskun Usta ◽  
Paolo Emilio Puddu ◽  
Ugo Papalia ◽  
Vincenzo De Santis ◽  
Domenico Vitale ◽  
...  

1998 ◽  
Vol 86 (1) ◽  
pp. 40-44 ◽  
Author(s):  
Ola P. Rosaeg ◽  
Nicholas J. Cicutti ◽  
Rosalind S. Labow

1998 ◽  
Vol 86 (1) ◽  
pp. 40-44 ◽  
Author(s):  
Ola P. Rosaeg ◽  
Nicholas J. Cicutti ◽  
Rosalind S. Labow

1997 ◽  
Vol 273 (2) ◽  
pp. H902-H908 ◽  
Author(s):  
J. C. Cleveland ◽  
D. R. Meldrum ◽  
R. T. Rowland ◽  
B. S. Cain ◽  
X. Meng ◽  
...  

The purposes of this study were to determine whether ischemic preconditioning (IPC) in human atrial trabeculae is mediated by alpha 1-adrenoceptors and protein kinase C (PKC) and whether the protection of IPC is replicated with alpha 1-adrenoceptor stimulation [alpha 1-adrenoceptor preconditioning (alpha 1-PC)]. Atrial trabeculae were obtained during coronary bypass surgery. The trabeculae were suspended in organ baths containing Tyrode solution and field stimulated at 1 Hz, and developed force was recorded. The trabeculae underwent 45 min of simulated ischemia (SI) and 120 min of reperfusion (I/R injury). IPC trabeculae received transient SI before I/R injury, alpha 1-Adrenoceptor blockade with BE-2254 and PKC inhibition with chelerythrine were independently combined with IPC before I/R injury. alpha 1-PC before I/R was examined with alpha 1-adrenergic agonist (phenylephrine) pre-treatment. Improved recovery of developed force and higher tissue creatine kinase activity were present in IPC trabeculae, and the protective effect of IPC was eliminated with either alpha 1-adrenoceptor blockade or PKC inhibition. alpha 1-PC trabeculae also exhibited enhanced functional recovery after I/R injury but lacked preservation of tissue creatine kinase activity. PKC inhibition eliminated the functional protection of alpha 1-PC. These results suggest that, in human atrial trabeculae, alpha 1-adrenoceptors and PKC mediate, in part, the functional and tissue CK preservation conferred by IPC, but alpha 1-PC does not replicate the protection of IPC.


Sign in / Sign up

Export Citation Format

Share Document